Belcaro G, Luzzi R, Hu S, Cesarone M R, Dugall M, Ippolito E, Corsi M, Caporale S
Irvine 3 Circulation/Vascular Labs, Department of Biomedical Sciences, Ch-Pe University, Pescara, Italy -
Panminerva Med. 2014 Mar;56(1):41-8.
The aim of the study was the evaluation of supplementation with Pycnogenol®, French maritime pine bark extract (registered trademark of Horphag Research Ltd.) to improve the effects of the management of psoriasis and reduce the need for treatments.
Patients (age range 30-45) with moderate/severe plaque psoriasis were included in a 12-week registry study that did not interfere with 'standard management'. The minimum Psoriasis Area Severity Index (PASI) score at inclusion was 10. Subjects with 10-29% (grade 2) and 30-49% (grade 3) of involved area were included. Oxidative stress (plasma free radicals) was measured. Patient-reported measures included the Dermatology Life Quality Index (DLQI). The supplement was used at a dosage of 150 mg/day (50 mg three times daily).
The two registry groups (standard management and standard management+supplementation) were comparable. Dropouts were due to logistical problems. Single PASI items were evaluated: a decrease in the affected body area in boths groups was observed. The decrease in affected areas was more pronounced in the Pycnogenol group in all body regions. The severity score (erythema, induration, desquamation) improved more significantly with Pycnogenol. Considering the water content of skin in all areas, the increase was higher with Pycnogenol. The quantity of exfoliating cells (score from -5 to +5) was significantly reduced in both groups, with a better action using Pycnogenol. Skin moisture improved with treatment in all subjects, with better effects using Pycnogenol. Using a modified (12 items) DLQI indicating how much psoriasis had affected the patient's life in the previous week, Pycnogenol-supplemented subjects performed better for each single parameter in comparison with standard management. Improvement in the treatment time (-32% in comparison with standard management) and costs (decreased on average 36.4% in comparison with standard management) were observed in the supplement group. A decrease in consumption of other drugs was observed with the supplement. Oxidative stress was significantly lower in the supplement group at 12 weeks.
These results indicate the efficacy of Pycnogenol supplementation in improving control of the most common clinical aspects of psoriasis and in reducing oxidative stress. Further studies may indicate the possible systemic or local use of Pycnogenol and its role in controlling side effects and costs of standard management.
本研究旨在评估补充碧萝芷®（法国滨海松树皮提取物，霍法格研究有限公司注册商标）对改善银屑病治疗效果及减少治疗需求的作用。
将年龄在30 - 45岁的中度/重度斑块状银屑病患者纳入一项为期12周的登记研究，该研究不干扰“标准治疗”。纳入时银屑病面积和严重程度指数（PASI）的最低评分是10分。纳入累及面积为10% - 29%（2级）和30% - 49%（3级）的受试者。测量氧化应激（血浆自由基）。患者报告的指标包括皮肤病生活质量指数（DLQI）。补充剂的使用剂量为每日150毫克（每日三次，每次50毫克）。
两个登记组（标准治疗组和标准治疗 + 补充剂组）具有可比性。退出研究是由于后勤问题。对PASI的单个项目进行了评估：两组的受累身体面积均有减少。在所有身体区域，碧萝芷组受累面积的减少更为明显。碧萝芷使严重程度评分（红斑、硬结及脱屑）改善更为显著。考虑到所有区域皮肤的含水量，碧萝芷组的增加幅度更大。两组的脱落细胞数量（评分从 - 5至 + 5）均显著减少，使用碧萝芷的效果更好。所有受试者的皮肤水分在治疗后均有所改善，使用碧萝芷效果更佳。使用改良版（1）的DLQI（12个项目）来表明银屑病在前一周对患者生活的影响程度，与标准治疗相比，补充碧萝芷的受试者在每个单项参数上表现更佳。补充剂组的治疗时间有所改善（与标准治疗相比减少32%），成本降低（与标准治疗相比平均降低36.4%）。观察到补充剂组其他药物的消耗量有所减少。在第12周时，补充剂组的氧化应激显著降低。
这些结果表明补充碧萝芷在改善银屑病最常见临床症状的控制及降低氧化应激方面具有疗效。进一步的研究可能会表明碧萝芷可能的全身或局部应用方式及其在控制标准治疗的副作用和成本方面的作用。 （注：这里的“改良版（1）”原文未明确说明，可能存在信息缺失，翻译时保留原文形式。）
